Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
Paksoy, Nail; KAHRAMAN, SEDA; Erul, Enes; Seyyar, Mustafa; GÜMÜŞAY, ÖZGE; Bayram, Ertugrul; Demirel, Burcin Cakan; Acar, Omer; AKSOY, SERCAN; Baytemur, Naziyet Kose; ŞAHİN, ELİF; ÇABUK, DEVRİM; BAŞARAN, Gül; PAYDAŞ, SEMRA; YAREN, ARZU; Guven, Deniz Can; Erdogan, Atike Pinar; Demirci, Umut; Yasar, Alper; BAYOĞLU, İBRAHİM VEDAT; HIZAL, MUTLU; Gulbagci, Burcu; Davarci, Sena Ece; Yilmaz, Funda; Dogan, Ozlem; Orhan, Sibel Oyucu; Aytac, Ali; KESKİNKILIÇ, MERVE; EYLEMER MOCAN, EDA; Unal, Olcun Umit; Aydin, Esra; Yucel, Hakan; Isik, Deniz; Eren, Onder; OYAN ULUÇ, BAŞAK; Ozcelik, Melike; HACIBEKİROĞLU, İLHAN; Aydiner, Adnan; Demir, Hacer; Oksuzoglu, Berna; Cilbir, Ebru; ÇUBUKÇU, ERDEM; Oktay, Esin; EROL, CİHAN; Okutur, Sadi Kerem; Yildirim, Nilgun; Alkan, Ali; Selcukbiricik, Fatih; Aksoy, Asude; Karakas, Yusuf; Ozkanli, Gulhan; Duman, Berna Bozkurt; Aydin, Dincer; Dulgar, Ozgecan; Er, Muhammed Muhiddin; Teker, Fatih; YAVUZŞEN, TUĞBA; Aykan, Musa Baris; Inal, Ali; Iriagac, Yakup; Kalkan, Nurhan Onal; Keser, Murat; Sakalar, Teoman; Menekse, Serkan; Kut, Engin; Bilgin, Burak; Karaoglanoglu, Muge; Sunar, Veli; Ozdemir, Ozlem; Turhal, Nazim Serdar; Karadurmus, Nuri; YALÇIN, BÜLENT; ŞENDUR, MEHMET ALİ NAHİT; KAYIKÇIOĞLU, Erkan; ÇETİN, Bülent
Description:
Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.
Show full item record